No recent analyst price targets found for CZMWF.
Latest News for CZMWF
Carl Zeiss Meditec: Why The Market Is Finally Recognizing The Recovery
Carl Zeiss Meditec has rebounded nearly 50% from its early 2026 lows, validating the recovery thesis after a severe medtech sector downturn. Despite a 40% earnings decline and 64% share price drop, CZMWY remains fundamentally sound, with established products, strong ownership, and resilience through downturns. I maintain a €65/share price target and rate CZMWY a 'Buy,' citing potential EBITA margin recovery to 15%…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CZMWF.
Senate Trading
No Senate trades found for CZMWF.
U.S. House Trading
No House trades found for CZMWF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.